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8 10 12 14
Patients with liver disease
Patients without liver disease
Less than 5 x lO6 orgs,
per g. [ lower limit of
counting method.]
TAB LE A
The intestinal flora of patients with cirrhosis and other subjects.
DUODENUM
S.G. coli St.f. St.v. St.an. Diph.
Patients with Cirrhosis
2 x 4-5 x 107 7-2 x 104 2*5 x 104 -
3 x 6*4 x 106 3 x 105 -
4 . not investigated
9 3-2 x 107 4 x 10®
18 - 6 x 10^ -
19 _
20 3'3 x 107 - - - 1.6 x 104
21 - 6.8 x 107 -
22 1 x 108 1-9 x 105 1*2 x 104 + - +
23 -
24 - - 1.4 x 103 +
25 5 x 106 - -
26 -
Patients with gastrfr-lrtestinal disorders
42 not investigated .
43 6 x 107 - - 1.2 x 105 " 1.7 x 104
44 not investigated .
45 not investigated .
46 not investigated .
47 6 x 105 -
48 - - - - -
49 - - 5x10"
50 - - ±
51 (a) 4 x 108 5.6 x 107 3«4 x 106
(b) 4*1 x 107 1.6 x 10' 1*6 x lOg -
52 3 x 106 1-1 x 105 7 x 103
53 1.2 x 109 1 x 105 -
54 _____
Healthy subjects
63 6 x 106 -
64 ±




69 - - ~ 3.7 x 104
JEJEUNUM
Mic. A lk. pyo. P. Bac. Lac. Others
3 x 103
2.3 x 106







2 x 10' 3 x 10,
3
C x 10'







1 x 10 5 ,
S.C. coll St.f. St.v. St.an. Diph. Mic.
•V- •-
[ A-h





























x 10° 1 x 106
+
8 x 10"-
6 x 10* 6 x 10*
4*4 x lO8*4-4 x'lO^
4 x 107












5 x 102 5 x 10*
1*1 x ID3
1-5 x 104 3*8 x 104
1>5 x 10*
S.C. = Total smear count. Coli = coliform orgs, including E. coli. , E.freundii, Klebsiella, Bact. cloacae and Paracolon bacilli. ! A A
j. _
St.f.r Strep.faecalis. St. v.a Strep viridans. Diph. = Diphtheroid organisms, Mic. = Micrococci. Alk. = Bact.alkaligenes.
112- = Ps. pvocyanea. P. = Proteus. Bac. = Bacteroides. Lac. = Lactobacilli. St.an. = Strep.anaerobic,
x = specimens taken after administration of chlortetracycline. Smear counts were only done in some cases,
numbers represent orgs, per ml of intestinal fluid or per gram of faeses.
± = a few colonies. j, ,,, \
V S
+ = moderate numbers of organisms. v :
+++ = many organisms.
- = organisms present in numbers below the upper limit of the counting method (102 per ml),
>
TAB LE A
The intestinal flora of patients with cirrhosis and other subjects.
P. 3ac. Lac. Others S.C. coli St. f. St. v.
JEJEUMM




- 2-4 x 10"
104
2 x 104 3 x 10|~f~ 4 x 10
c— o







3 x 106 4«4 x 106
9 x 10? 3*2x10^*2*8 x'io3
2 x 10- 7 x 105
3 x 104
mm 3*9 x 104 1*7 X 104
~ 2*6 x 10® 2 X 108
1*1 X 10 2* 4 x 10° 1*3 X 108
lot
10°
- 2*4 x 104 2-5 X
1 X 10s 6*3 X










y~$» 4 x 10 Anitratum
«• ^^JY'2 x 103 Staph, pyog.








4*4 x 10®* 4« 4 x io^
















5 x 102 5 x 102







t.cloacae and paracolon bacilli,
cci. Alk. = Bact.alkaligenes.
acilli. St. an. = Strep, anaerobic,
n some cases.
ILEUM
TAB "LE A (Cont'd)
The intestinal flora of patients with cirrhosis and other subjects.
S.C. coli 3t.f. St. v. Sfe. an. Diph. Mic. A lk. pyo. ?. 3ae. Lac. Others S. C. coli St.f.
Patients with cirrhosis
2 X 4. 3 x 01—t 9.6 X 10I 1-8 X 107 _ — _ _ — „ 1-2 x 107
2 x 108
_




9.4 X 107 6 X 107 -
106
- _ - - -
9 3 x 2-2 X 107 - 1 X - - 4 X 105 + -
18 - 2 X 105 - - - - -
19 - - - 4 x 103 _ - - 1-2 x 105
20 * - 1 X 105 1*2 X 104 _ _ - - — "
21 3.7 X 107 4.8 X 107 - - _ - - - - -
22 7 x 107 1 X 107 2-7 X 106 - _ _ _ 1*6 X 103 ~
23 - 4.7 X 103 1* 9 X 104 - - — 4 X 102 - - -
24 6 x 100 8 X 102 1-8 X 106 Jb _ O - ~ 3
25 4 x 102 - -
102
1*5 x +FOO1—1 1 x 10 ~ - ~ -
26 - - 3 X _ _ ~ - - - — —










x 10 Staph, albus




1 x 107 8 x 107
3-2 x 108 9*9 x 108
4 x 107
8» 2 x 104 4.5 x 104
6*2 x 105
6 x 102 6 x 102
4'2 x 103









50- - ± ~
51 (a) )not investigated
(b) )not investigated
62 2.8 x 107 1.2 x 105
53 2 x 108 105 - " ~













1*2 x 107 2 x 103 8*5 x 104
1-5 x 103
2 x 102
1*8 x 108 1 x 103





































»»= lower limit of counting
TAB M A (Cont'd)











I -9»5 X ioio 4-3 X 1Oq 9 X
?,L 9*5 X ioj-21O10
1 X 10o 1-5 X1
9.1 X 2*4 X 109 5 X
Anitratuk '




6 X 107 mm
Staph, jyeg. 5 X 2*4 X 109 —
'
9-3 X 9 X 108 7 X
1* 6 X 8 X 10s _
Staph, albus










5 X 109 — _ 2«5 x
2»5 X 109 ± 4 X











•y 1 fw •+•X 10






2* 5 x 107 (P)







1* 5 x 10§ - - g.5 x 108
lxio: - - 3 x io9
1.1 x 10d 2 x 109 4 x 10^-9 5 x 108




not investigated . . .
not invest igated ...
1*5 X 108 4 X 108 _ M •a,
2*5 X 105
109
1 X 106 5 X 109 -
O CO
- -
1«1 X - -
108
6 X 108 1*7 X - -
3 X 10l - 5 X 2 X 109 - — -
1 X 1°8 2 x 107 5 X 10b 5 X 108
1*4 x 109
-
1-1 X 108 _ 2*5 X 107 2.5 X 109 1 X 109 -
= lower limit of counting method = 5 x 10s for aerobes and 5 x 107 for anaerobes.
TABLE B
A Comparison of the faecal flora of patients with cirrhosis of the liver and. of patients without liver disease.










































55 2* 1 X IQlO 1 X 108
10i56 1010
1.5 X 108 1.4 X 10l 2-5 X
57 4 X 6 X 107 4 X 108 5-5 X 108
58 8-5 X 1010 5-5 X 107 2-5 X 107 5 X 108
59 2*4 X 109 2-5 X 109
60 3*3 X 108 3- 5 X 107 3 X 109
61 2-8 X 107
1010
2*3 X 109
62 7 X 108 1 X 3 X 109
70 1.5 X 107 5 X 109
71 7.4 X 1010 8 X 108 8 X 107 2*5 X 109
72 3-4 X 1010 2-3 X 108 5 X 10b 2 X 108
73 1-3 X 108 1-5 X 107 1*3 X 10Q
74 1-5 X 107 9-3 X 108 1*2 X 109
75 1*1 X 1010 7-5 X 108 1 X 1010
76 1-4 X 10P 4*1 X 10Q + + 10977 1 X 10d 2-5 X 108 9-4 X












































































1 X 2 X CO01—! 2 X 108 1*2 X 109
107 3 X 109
108109 9 X 108 1 X 1* 5 X H 0 0:
101 8 X 109
10q 1-7 X 109109
108 2* 4 X 109
109 2 X 109
106107 3« 3 X 107 5*3 X
10? 7 X loio 1 X 109 4 X 106107




















5 x 107 3*2 x 108 (Micrococcus)
5 x 108
+++ = profuse growth (Colonies not counted)
± = a few colonies.
Smear counts done in some cases only.
taI&E G
Biochemical findings in intestinal aspirates and the effect Jfjbf incubation of ileal fluid under various conditions on
__ the pH and the contents of ammonia, .^methionine, amines and mei'capkans.
Concentrations of ammonia nitrogen (NH^) .Sjfend methionine (Meth) in ys Per





JrfL NH/ Meth Am Mec J>IL pH
Cirrhosis of the Liver
Mean
2 7* 7 20 70 - -
3 8»1 33 33 0 0
9 7*5 66 98 - 0
18 8*1 0 17 0 0
19x 00•c- 28 61 0 0
20 8« 0 6 108 - 0
21 7.7 8 98 0 0
23 6*3 6 83 0 0
24 8.1 10 16 - 0
25 8.4 5 6 0 0
26 6.4 28 21 0 0









ILEAL FLUID: CHANGES AFTER INCUBATION
+Water +Methionine +Glucose +Glucose +Methionine









































































































NH/ Meth Am Mec
'2*8 +52 +9 0











































pH NH/ Meth Am Me c
-2-8 + 56 -111 + 0








NH/ Meth Am Mec
-0*1 +10 -7











-2« 0 +9 -74
+0.1 +1 +6 0 0 +0.8 +7 -29 0 0
+ 0» 6 +2 -11 0 0 + 0* 5 +10 -20 0 0


































-1*6 + 56 •50


























Ileal juice incubated with Lactose: pH -2*9, NH4 +39, Meth -9, Incubated Lactose and methionine pH











Bacterial growth and ammonia production in Ileal fluid during incubation.
Figures represent ammonia in jig N/ml. Bacterial growth is expressed semi-quantitatively (See P V-6 ).
Subject's Organisms Initial Content
No.
Content after Incubation with
Water Glucose Methionine Methionine Methionine Methionine
+ Glucose + Chlortetracycline + Glucose
+ Chlortetracycline
Patients with Cirrhosis 20




































-9 +39' +71 +13' -6'
+++ - - ±
+++ — +++ +++ —
- — +++ +++ —
+++ +++
— + — — -




























J / r -




j s "i\ ^
,tii .*• . .I. . M. • .Iv- - .it A
+ 19 ++
? H—H+











+25 +10 -6 +3
+++ +++ ++ ++









































+2 +1 +10 +40 +5 +61
- +++ - +
++ ++-|.
++ ++ -
— — — — ++ ++
— — — +++ — —
Mean 17 + 138 +55 +116 +41 0 +14
' Lactose added instead of glucose.
"Respiratory Organisms" include one or more of the following: Strep.viridans, Micrococci, Staph, albus and Diphtheroids.
TA: I
Bacterial growth and changes in Metiioinine-
Figures represent Metlioinine in ug N/ml. Bacterif
E
ontent of ileal fluid during incubation
growth is expressed semi-quant itatively (See P 'fb ).
Subject's organisms Initial content
No
Water Glucose Methionine Methionine Methionine Methionine
































+ 9 -9' -158 -40' -12'
_ - +++ _ +
H—H4 M +i-4- 4-4*4- «,
— — 444 -1-4-4- «.































E.coli . . +
E.freundii ±
1 -30 +2 -276 -10
+++ +++ +++ ++





































. -29 -85 -10 -8
f 444 444 _n*r













-20 -141 -41 -90
+++
_ .j.
H—h ■+—++ _ „
_ _ ++ ++
_ +++ _ _
Mean 63 + 75 +2 -157 -50 -20 -18
' Lactose added instead of glucose.









S.C. Coli St.f. St. an. 3ac. Lac. CI. w. Others
24.10x
28.10
2*5 x 1010 4.3 x 108
3* 2 x 108
5 x 10'
6 x 108
24. 9X 1 X 106 2*2 X 108
27.7 1 X 108 1*1 X 108






13.4 - 20.4 13.4 6*2 X 1010 9 X CO01—i 8.5 X 108 - 4.5 X 109 ~ - -
3 (C) 25.11 5* 5 X ioio 5*5 X 10Z 6 X 108 3 X 108 M m
27.11 3*8 X 1010 4>6 X 108 6 X io? - 2 X 109 • « -
27.11 - 2.12
104 108 101022. 3X -
loll
2-7 X 7 X - 1.3 X
GO1.ID 5.4 1*2 X 4.7 X 108 1«4 X 109 — 8 X 1010 — "* 1«1 x 109 St.albus
19.5 - 27.5 19.5 _ 4*5 X 107 - - 1 X 1010 2 x 108 2 x 108 1 x 109 St.albus
16.llx 3«6 X 1010 2-5 X 109 5 X 107 3 X 109
4 (D) 23.11 2.9 X 1010 1*1 X iO8 3 X lO? 4*6 X 108 9-9 X 108 — mm
24.11 5-2 X 1010 5.9 X 109 9 X 107 7.5 x 108 1*5 X 109 - . -
27*11 - 3.12
2.4 - 5.4 2.4 3«5 x 108 1«5 x 10* 8 x 109
5 (E) 2.3X 5.3 X 108 1.3 X 109 — 9 X 108 — 1 X 108 1.5 X
4* 3X 3 X 108 2*2 X 109
10s
5 X 108 - 2 X 108 -
13.3 - 21.3 7. 3X 4.5 x 1010 1.1 X 108 1 X 108 9 x 1*3 X 109 - 1-5 X 10s -
10.3 4.4 X 108 8-5 X 108 - + 0 + + -
12.3 1.3 X 10s 4.5 X 108 8 x 108 7.5 X 108 - 7.5 X 108 _
i8 (Mic)
7.5 - 13.5
x Specimens not shown in diagrams.





of Chlortetracycline on the faecal flora.
FAECES DURING THERAPY
■. Date s.c. Coli P. St.f. St.f. (H) St. an. Bac. Lac. CI. w. Others
1.11
/• -AH





6*3 x 109 2-3 x 107
1 X 106 5*6 x 107 1-1 x 107 - -




































4*7 x 108 St.albus
21.5
27.5
- 5 x 106
5 x 10s 1 x 109
5 x 109 1*2 x 109
2*5 x 109






8* 7 x 109

























3» 5 x 1010
mm »
1 x 108




















2* 5 x 108
6*5 x 10s 1 x 109
6 x 108 2 x 10°
1 x 1019 — 6*5 x 108
-
FAECES AFTER THERAPY
Date S.C. Coli P. St. f. St. f. (H) St. an. Bac. Lac. CI. w. Others









4*9 X 1010 4 X 10v 1-8 X 7 x _ 5 x + am ra
10.12x — 1-1 X 107 5 x 109 - - - 5 x 1010 - - 1*1 X
6.10 6 x 10® 1*4 X 10® 2-2 X 1°7 4*3 X 107 _ .





- - - 9-6 X 10l 2*4 X !°7 2*4 x 6*4 X 107
19.10x 4 X -
log10°
- 9*9 X 107 2*5 X 108 _ 4 X 107
10'21.10x 2*9 X 1010 1*3 X -
108
108108
2-5 x 107 -
10®
1 x 10s _ 3*7 X -










10. lx 3*1 X 1*1 X 6 x - - -
1010
1 x 1 X -
28.2X 1*3 X loll 6* 5 X 1°|108
- -
109
- 1*1 x 6 x !°9 - —
10. 3X 6*5 X 1010 2*3 X - 1 x - - 3*2 x 109 ~ — —
15. 3X 3.7 X 1010 8 X 108 - - _ _ + + - -




































2 x 108 (St.albus)
5.12 3 x 1010 9*9 x 108 1
9.12 -
1010
4-8 x 109 5
28.12x 2*2 x 1*5 x 107
15. 2X 6*9 x IqIO 2*6 x 10q 2
4.3X 8-5 x 1010 1*8 x 109 5
14.3X 7-5 X 1010 8*4 x iO8
24. 3X - 1-2 x 109
27.3X — 2.6 x 109
14.4 «n 2*5












































1 x 10' 5 x log
1.3 x 109
5 x 10'
3* 3 x 109
3 x 109 5 x 109
13.8 - 21.8
SU3JECTS WITHOUT LIVER DISEASE
BEFORE THERAPY






4 x 1010 1 x 107
3*3 x 108 3.5 X 107 3 x 109
6 X 109




12.8 2»5 x 108 5 x 107 2.3 x 109
70 (V)
9.2 - 12.2
9.2 3*2 x 106 1*5 x 105 4 x 108 9 x 10s
71 (W)
22.2 - 25.2
































1 X 109 2*2 x 109 2*1 x 109 - - - 2*7 x 108 (St.pyogenes)
- - ~ - _ - - - - -








— 1.5 x 109
_ - - -
2*8 x 109(St.pyogenes)
1*5 x 109 (Mic)
27.2 - - - 3 x 108 _ - - _ _ -
__




1 x 10 (St.albus)
13.6
MM
6*5 x 108 5 X 106 5 x 106 mm 1 X ie8
-




















Date S.C. Coli P. St.f. St.f. (H) St.an. Bac. Lac. Cl.w. Others
18.2 6*3 x 1010 - 4-8 x 108 1-8 x 1CP - 3-6 x 109 -
25.2 5*1 x 1010 3*6 x 108 1.1 x 109 - 3-5 x 109 - 1 x 109 - - 1 x 109 (Mic)










11.3 7*5 x 109 - 10? 3 x 10? 1-1 x 109 2-3 x 108
19.3 ±3* 5 x 108 1 x 109 2 x 109 7 x 109
22.3 2*4 x 108 x 2 x 107 1 x 108 - 2*5 x 108 3 x 109
28. 5X 6*4 x 10^? 5 x 109 5 x 107 1 x 10° - 9 x 108 5 x 109
14. 4X 4 x 1010 2*8 x 108 - 8« 5 x 107 5 x 107 1»3 x 109 6*7 x 108
25.4 - - - x « - 1-9 x 10® -
3.5 - 6 x 108 xlO 1 x 109 2 x 109 7.5 x 108
11.8 ~ 2-5 x 108
16.8 - 5 x 108
18.2 - 1-3 x 10l0 8 x 109 2.8 x 108 ~ - 8 x 108 2'7 x 109
25.2 - 7-4 x 1010 5 x 109 - 1-9 x 109 1-2 x 109 5 x 109 8 x 109
4.3X - " 2*6 x 109 - ~ - 1«3 x 109 7-5 x 109
8.3X ~ 4-7 x 1010 6 xlO8 - 6 x 10° " 6 x 108 "in
17.3X - 1.2 x 1011 1*5 x 108 " 6 x 109 - - 1*2 x 10±u
22. 3X " - 8 x 108 - 9 x 107 - - ± 1-3 x 109
_ •» "** ™" "** """ mm mm
^
_________ -
29.6 - 1 x 108 1 x 107 1 x 108 " ~
_ _ - -
25.6 - - 7.5 x 109 1*5 x 109 - 1 x 108 - 3 x 109
1.7 - 2*5 x 108 1*2 x 109
7.7 - 2.8 x 108 9 x 107 1«5 x 108 - - 1 x 1010 - -
23.8 - 8*5 x 107 1*5 x 10? 1*5 x 108 - -
25.8 - 2.8 x 109 7* 5 x 107 1«1 x 109
fVLo 7-7''O<0 Z-r'tO* V-S^/o7 - - - , x-1*;V1 - ^-9* co9 1 - - - -
BEFORE THERAPY




9.2 4* 3 x lO^-O 9*4 x 108 1 x 108 1* 7 x 109
3.3 - 8.3






10.2 3* 6 x 1010 1* 6 x 109 2.8 x 109 1*9 x 109 2*7 x 109
18 (H)
10.7 ~ 18.7
























I Mo1 Uio 1
DURING THERAPY
TABLE F (III).
Date S.C. Coli P. St.f. St.f. (H) St.an. Bac. Lac. Cl.w. Others
10.2 - 6 x 107 - - - 3*5 x 108
11.2 4-4 x 10i0 1 x 109 - 1-5 x 107 - 2-1 x 109 7*5 x 108 2*3 x 109
13.8 - 2-5 x loZ - 1-1 x 10® - - 5 x 10°
15.8 - 4-7 x 10® 8 x 107 1-6 x 108 -
17.8 - 1-2 x 109 - 5 x 109
15.8 1-3 x 109 - - - - 1-3 x 109
18.8 - 1*8 x 109 2-5 x 107 2-3 x 109 - 8-5 x 108
20.8 - 1-2 x 10s 3 x 108 3 x 109 - - - +
10.2 - 1-5 x 10s - - - - 5 x 109
16.2 - 1 • 2 x 109 - - - 1*2 x 109
24.2 6 x 1010 8 x 108 - - 2-6 x 109
25.2 2.7 x 1010 - - 2-5 x 109 2-8 x lOlO
14.8 - 1 x 10tt - _ 2*5 x 108 - - 9*4 x 109
18.8 - 2 x 108 7 x 10° - 3* 5 x 108 1-3 x 109
20.8 - 1*8 x 109 - - 2*5 x 108 8' 5 x 108
AFTER THERAPY
Date S.G. Coli P. St.f. St.f. (H) St. an. Bae. Lac. Cl.w. Others
14.2 1*9 x 1010 1*3 x 109 6-5 x 108 2-5 x 109 - - — _ 1 x 109
18.2 - 5* 5 x 107 - 1*5 x 107 - - 4 x 10y
14.2 9 x 109 1 x 10? 1 x 108 1*8 x 109 - - - 2 x 108
> * - ■■ ■- " 11 1 "■ ■ - ■ ■ ■■ ' —. ■ " ■ ■ - ■■ 1 ■ - ■
28.2 3.7 x 1010 1*1 x 109 - 1 x 109 6-2 x 109
23.8 7* 9 x 109 4* 5 x 107 5-5 x 109
29.8 1*3 x 108 - 3*5 x 107 " 4*3 x 109
TABLE G
Ammonia production by gram positive bacteria.
Cultures grown in Amino Acid medium containing 0*5% glucose.
NHu production and growth in yig N/ml.
PH 6 ( 7A 7 8
Species Growth NH#= production Growth NH;^r product ior
i i








Mean ± S.D. 182(±91) 40(±6)
10 0 30 3
15 2 16 2 37 3
4 2 24 4 15 12
Lactobacillus 63 5 43 4 10 19
17 6 10 5
Plantarum 66 8 46 5
39 7
















































Mean ± S.D. 2K+27) 14(±13)
table m
Ammonia production by gram negative organisms in the amnio acid medium.
Glucose when present at concentration of 0*5%,
NH4 production and bacterial growth (Turbidity) in jig N/ml.
TT b
Glucose








































































































































































Mean ± S.D. ■j 4(±2) 13(±7) 13 (+23) 17(±6) 2(±2) 16(±6)
TABLE X
The effect of chlortetracycline at concentrations .just limiting growth
on NH4 production growth and NH4 in yig N/ml.

















































































































The relationship of gastric and duodenal acidity to the "bacterial population of the small intestine
BACTERIOLOGY
Subject's Gastric Duodenal
































19 1- 8 Candida 6*7 x 10® Lactobacilli 7 x 104
M. c it reus 1*7 x 10® Staph, pyogenes 2 x 10®
Candida 2 x 10®
Staph.pyogenes 1 x 10®
Candida 1 x 10®









1 x 10c Bact.coli 3 x 10^
Strep.faecalis 2 x 10
Bact.coli 5 x 10'
Micrococcus 8*4 x 10);
Diphtheroids 4*2 x 10):
Strep, viridans 1*7 x 10"
steri Bact.coli 2 x 10'
Strep.faecalis 2 x 10'
Bact.coli 5 x 10
Strep.faecalis 2 x 10
Ps.pyocyanea 4 x 102
25 1-8 steri Bact. coli 3 x 10
Strep.viridans +
Ps.pyocyanea 1 x 10
Bact.coli 4 x lot
Strep.viridans 1 x 10^
Ps.pyocyanea 1 x 102












44 Bact.coli 4 x 10
Strep.faecalis 4 x 10?
Bact.coli 1 x 10?
Strep.faecalis 8 x 10?








Ps.pyocyanea 2 x 10'
48 2» 1 sterile
steri^
Bact. coli 1 x 10"
Strep.faecalis 3 x 10'
Bact. coli 8 x 10








St rep. viridans 2 x 10S
Anaerobic strep.1 x 10
Strep, viridans 5*5 x 104 Strep, viridans! 1 x 10® Strep.viridans 5 x 102
Anaerobic strep.5 x 102
Bact. alkalig. 3 x 10£
66 1-7 sterile sterile sterile Bact.coli 1 x 10"
Bact.alkalig. 1 x 10








Strep.viridans 1 x 10®
Lactobacilli 5 x 10®
Strep.viridans 5 x 10~
Lactobacilli 1 x 10°
1 s free acid present in test meal in normal or increased amounts,
i = a few colonies isolated.
+ = moderate numbers isolated but not counted
/»
I z this aspirate was repeated and the results were Bact.coli 1*2 x 10
Micrococcus +
Strep.viridans +
"Bact.coli" includes all gram negative lactose fermenting organisms.
TABLE |_
A Comparison of the types of conform organisms isolated from faeces and ileum




No. Typical E. coli Atypical colIform organisms "Typ'ical E.coll Atypical coliform organisms
number antigen L G M D Sue Sal number antigen ru G M D Sue Sal number antigen L G M D Sue Sal number antigen L G M D Sue Sal
2 8 x 108 09 + 4 4 4 4 0 x 109 TTlI1 4 4- + 4 -1- 4- 07 + + 4 + 4 F 4-4-4-4- 4- mm
4- 0? 444- + -
3 4 091 + 4 4- - + 4 4* 4 + 4- 091 4 + -i- - •J. 4- 4* 4- 4* 4. -
4 + ? + + + - -h — 4- F 4 4- - 4* + F 4- 4- 4- — + 4
4- F 4 4- + _ - -
9 4 9 -f- + + - _ i 4* 9 + -!- + .-
18 + 9 4~ 4-4-4- 4
6 x lO7
+ K 4- 4- 4- — 4* +
19 F 4 4_ + _ 4.
.•5 x 108 K 4 + + - 4. +
22 + F 4 + 4 - - - 4- 06 4 4 4 - + Kg3 4- 4- -!- — 4- 4
Eiy + + 4 4 4- +
* 4 + + - + +
23 4 081 + 4- 4- - 4 + F 4* 4- 4- - i _
25 4 9 JL JL J. - _ 4- 9 X J. ± - - + F 4- 4- 4- - - -
4 ? + 4 4 4 - 4- 9 4 4 4 — — —
26 4 9 4~ 4-4-4" + *■















4 414 ± "1
64 + 432 + 4 4 - - 4
4 088 + + 4 4 _ 4




















2 X 0? + + 4 4 - _
67 4 9 + + 4 4 ± -
? + + 4 4 _ 4











11) Subjects without liver disease
I! 6 x 105 ?4 + 4 - 4 4 4 4 + ±
+ F





1 x 102 0? + + 4 + 4 1*5 x 10
3
F + + + + +
4 F 4- + +
+ + + + + +
No. of subjects from whom,
isolated
8
Numbers of orgs expressed per g. in the case of faeces,, per ml. in the case of ileal fluid.
+ = number of orgs not counted. - = orgs present in numbers below the lower limit of the counting method.
The number following an 0 or H indicates the antigenic composition of E.coli strains. 0? = unknown 0 groups.
F = E. freundii, K = Klebsiella. The number following K indicates the capsular type.
L, G, M, D, Sue, Sal indicates fermentation of lactose, glucose, Maneitol, Dulcitol, Sucrose and Selicin. +
Faecal and ileal strains, put in red, were identical biochemically and in some cases antigenifeilly.
Fx = Strain of E. freund.il identical also by colicine typing.
_L =
0 group not determined.
Fermentation with acid and gas
Fermentation u t» n
production of acid only.
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Nitrogenous substances given to certain patients with hepatic cirrhosis can
precipitate neurological changes, indistinguishable from spontaneous hepatic coma
(17, 23, 38, 47, 49). These include a high protein diet, ammonium salts and urea.
There have also been reports that methionine, an amino-acid often recommended
for the treatment of liver disease, might have a similar action. Watson (53) reports
a patient with cirrhosis developing confusion after 8 g. methionine and Kinsell
and co-workers (22) describe a patient with cirrhosis who became mentally dis¬
orientated when given 9 g. dl-methionine daily for three days. Singh, Barclay
and Cooke (48) noted neurological deterioration in a patient with hepatic cirrhosis
after 10 g. dl-methionine by mouth, and similar changes directly attributable to
methionine have been reported in four other patients with hepatic cirrhosis (37,
47). The present paper describes investigations into the mechanism of methionine
toxicity and the effect of chlortetracycline in delaying the development of symptoms.
Patients studied.
Twenty-eight patients with liver disease were investigated. Patients one to
nine who were studied in detail suffered from cirrhosis of the liver and had previously
experienced episodes of impending hepatic coma {Chronic portal systemic encephalo¬
pathy). Electroencephalograms were compatible with this diagnosis; In eight,
the extent of the portal venous collateral circulation was assessed by transplenic
portal venography (1) and a very extensive collateral circulation was demonstrated.
In the ninth patient (Case seven) disturbance of the blood clotting mechanism
prohibited this investigation.
In addition fifteen patients were observed with portal cirrhosis, one patient
with biliary cirrhosis, one patient with extra-hepatic portal vein obstruction without
cirrhosis and two patients with acute virus hepatitis. Six of these patients had
previously experienced the neurological complications of liver disease (Table I).
Twelve patients were included, suffering from non-hepatic diseases.
* Working with a grant from the Medical Research Council.
We wish to thank Dr. C. Dalgleish for biochemical advice, Dr. W. Hayes for guidance in the
bacteriological studies, Dr. Harriet J. Warrack of the Wellcome Foundation for typing Clostridium
Welchii strains, and Sisters B. D. Griffiths, S.R.N, and P. R. Richards, S.R.N, for enthusiastic
nursing co-operation.
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Methods.
Neuro-psychiatric assessment.
The degree of neurological disorder was assessed by two independent observers.
The following grades were recognised:
0 Normal.
1 Trivial lack of awareness, apathy or euphoria with or without objective
neurological signs.
2 Obvious personality change, with neurological abnormality; gross facade
of personality preserved.
3 Advanced confusion and disorientation.
4 Stuporose but responsive.
5 Comatose.
Biochemical methods.
Blood ammonium levels were estimated by a slight modification of Conway's
method (12, 37).
Plasma dl-methionine, — plasma 1 ml. was de-proteinised with 5 ml. acetone.
After evaporation of acetone, it was desalted by the Dent modification of the Consden,
Gordon and Martin method (11). Volumes of each specimen containing 1-30 (ag.
methionine, together with a range of standards, were run on buffered one-way
chromatograms (28). After lightly spraying with ninhydrin, the concentration of
amino-acid in each methionine spot and hence in the original specimen was estimated
either by the method of Yemm and Cocking (56) or that of Naftalin (34).
Blood bicarbonate, serum bilirubin and albumin were estimated by routine
procedures and arterial blood pH by the method of Rosenthal (43).
Bacteriological methods.
Fresh feces (200 mg.) were weighed on a clean piece of X-ray film and placed
in a bottle containing 100 ml. of 0-85% sodium chloride solution. The bottle was
shaken at 37°C. for one hour at 270 oscillations a minute, for homogenization.
A standard loopful (0-01 ml.) of a 1: 100 dilution in saline of this suspension
was spread evenly over plates containing the following media:
(A) Blood agar.
(B) Blood agar containing 6% agar (20).
(C) MacConkey's medium.
in some cases Sabouraud's medium was used in addition. These plates were
incubated aerobically for 48 hours.
For anaerobic cultivation 0-01 ml. of a 1 : 1,000 dilution of the original suspension
was spread on—
(A) Blood agar
(B) Blood agar containing 6% agar and incubated for 48 hours anaerobically
in a Fildes-Mclntosh jar containing 5% C02.
A tomato agar medium for lactobacilli (5) and Fildes peptic blood digest
medium for Bacteroides (45) were also used in several cases.
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table
Effect of daily oral methionine with and without chlortetracycline on
Methionine alone
Days of control perioc Days after start of ir ethionine
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IT.
the neurological condition, hlooil methionine and ammonium (NH4N) levels.
Methionine and chlortetracyclinc
feeding Days of control period Days after start of methionine feeding
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TABLE II
Methionine alone
Days of control period Days after start of methionine
















































































































































Bacterial metabolism ofmethionine in vitro.
Strains of Bact. coli and Proteus vulgaris were grown in 05% glucose broth
for 24 hours, washed in 0-85% saline and resuspended in 0-02M phosphate buffer
at pH 6 and pH 8. Since the pH in the intestine is variable (30) 1,000 pgm
methionine/ml. was added to the suspensions which contained approx. 70 (xgm/ml.
total nitrogen. A Bacteroides strain was grown in 0-5% glucose broth for 48 hours
in a Fildes-Mclntosh jar and then a similar suspension was prepared. The effect
of the addition of 2-5 [ag./ml. glucose on methionine breakdown was studied in all
species and that of 5 jxg./ml. chlortetracycline in Bact. coli and Pr. vulgaris.
Chlortetracycline was not added to Bacteroides suspensions, since these organisms
disappear from the gut when the antibiotic is administered. Anaerobic conditions
for Bacteroides were obtained by the addition of 0T mg./ml. thioacetic acid.
Production'of sulphates (25)jandjamines"(4)jwere measured.
Methionine was given to patients with liver disease with their consent and
co-operation as part of a necessary assessment of their mental and neurological
condition or as a preliminary to consideration of porta-caval anastomosis. Patients
—continued.

















Doses of methionine in grams. Chlortctracycline 2 g. per day started 2 days before
methionine.
CNS—neurological grade.
Blood levels of NH4N (normal < 1) and methionine (normal < 20) in iig./ml..
f Patients who had experienced neurological complications.
* Values before commencing methionine.
with severe impairment of liver function were excluded. Dietary protein intake
was maintained constant during the period of observation. Patients with neuro¬
logical complications had been under observation in hosptial for at least one week
and the neurological condition was steady.
Enteric coated tablets containing 250 mg. dl-methionine were given in divided
doses between 6 a.m. and 9 p.m.. The total daily dose, usually 10 g., varied between
8 and 20 g.. Two patients received two courses. The drug was withdrawn when
unequivocal neurological deterioration occurred or after five to seven days. Blood
levels of methionine, ammonium, bicarbonate and serum bilirubin were estimated
at intervals during the control period, during the administration of methionine and
following its withdrawal.
In ten patients, 6 g. methionine in 300 ml. 5% dextrose was given intravenously
at a constant rate during a 30 minute period. Peripheral blood samples were
taken before the infusion and 15, 60, 120 and 240 minutes after its completion and
analysed for methionine and ammonium.
Five patients sensitive to methionine by mouth later received chlortetracycline
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methionine. Both drugs were stopped simultaneously. In these patients feces
were collected before starting chlortetracycline, when the patient was receiving




The effect of oral methionine (Tables II and III). The drug imparted a
characteristic odour to the breath and rarely caused slight nausea.
Neurological status. Nine patients had portal cirrhosis and pre-existing
neurological complications associated with an extensive portal systemic collateral
circulation. During the administration of methionine, neurological deterioration
of at least two grades occurred in seven (patients 1 to 7) and in two, this effect was
reproduced when the drug was administered a second time. Changes followed a
similar pattern to those seen during spontaneous deterioration. They occurred
from one to four days after commencing and after total doses of 11 to 46 g.
methionine. Two of the patients (No. 8 and 9) tolerated 80 and 99 g. methionine
without neurological change.
Seven patients with portal cirrhosis (patients 10 to 16) who had never exhibited
neurological complications, tolerated 50-102 g. methionine without neurological
change. Liver function was considered to be less severely impaired than in the
patients who were sensitive to the drug and an extensive collateral circulation was
demonstrated in only three (patients 10, 15, 16). The patient with extra-hepatic
portal vein obstruction (patient 20) also showed no change.
Blood ammonium levels. Control fasting blood ammonium levels were raised
in five of the seven patients who later deteriorated with methionine. There was
an inconstant change following methionine, the level rising five times, remaining
unchanged once and falling on three occasions. The mean level at the height of
deterioration showed no significant difference from the control values.
Two patients who had previously experienced neurological complications, but
were unaffected by oral methionine, had raised control blood ammonium levels.
In one instance, methionine was followed by a rise and in the other by a fall in the
blood ammonium level.
Eight patients without neurological changes showed an inconstant change in
the blood ammonium level after methionine.
Bloodmethionine levels. In four patients who later deteriorated after methionine,
the control blood methionine levels were normal in two and raised in two. The
level was increased in one and normal in five of the patients who were unaffected
by methionine feeding.
In both groups, the rise in blood methionine level after methionine administration
was comparable.
Serum bilirubin levels and evidence of acidosis. Serum bilirubin level did not
change after methionine feeding (Table IV).
There was no clinical evidence of increasing acidosis. The serum bicarbonate
showed a slight but significant decrease (P = 0 01). In two patients in which it
was measured, the arterial pH did not change. In one patient the renal compensatory
mechanisms were studied before and after seven days of methionine administration
(total dose: 70 g.) and was found to be adequate. Titratable urinary acid rose
from 38 to 87 mEq. per day (normal value 20-50), while urinary NH4 rose from 25
to 126 mEq. daily (normal average value 50).
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TABLE IV.
Serum bilirubin and blood bicarbonate levels before
and after the administration of oral methionine.
Control levels Levels after methionine
Patient
Plasma biliburin Blood bicarbonate Plasma bilirubin Blood bicarbonate
(mg./lOO ml.) (mEq./l.) (mg./lOO ml.) (mEq./I.)
It 0-9 0-9
2t 3-8 24-0 1-7 22-7
4t 2-2 27-3 2-1 —
5f 0-5 27-9 2-7 26-8
5* 2-3 27-1 1-6 25-6
6f 2-2 — 2-4 23-8
8t 0-5 — 1-6 —
9f 0-8 26-2 1-2 21 '8
10 1-5 28-5 1-2 25-1
28f 1-3 23-0 1-3 21-0
Mean 1-6 26-3 1-7 23-8
t Neurological deterioration after methionine.
* Methionine given with chlortetracycline.
Effect of intravenous methionine. Intravenous methionine was given to four
patients who had previously deteriorated with oral methionine. In three there was
no change in neurological status and in the fourth there was " two-grade"
deterioration, occurring two hours after stopping the infusion (Table V).
Six patients without previous neurological changes were unaffected by the
infusion.
There was no conspicuous change in blood ammonium level, except in the
patient who showed neurological deterioration when the methionine was stopped.
In this patient the level rose from 2-7 to 4-1 (xg./ml..
Methionine tolerance was impaired in all seven patients with liver disease
(patients 1, 2, 3, 4, 17, 18, 19) and blood methionine levels remained elevated four
hours after stopping the infusion while in three normal subjects (patients 29, 30,
31) control values were regained within four hours of the infusion.
Effect of chlortetracycline on methionine toxicity. Five patients who had
previously deteriorated when given oral methionine were completely or partially
protected by the simultaneous administration of chlortetracycline (Tables II, III).
Blood methionine levels were higher than those obtained with methionine alone.
Blood ammonium levels did not show any conspicuous change during administration
of chlortetracycline with methionine, but levels recorded when the drugs were
withdrawn were usually lower than those recorded at the height of deterioration
following methionine alone.
Conclusions. Oral methionine is toxic to some patients with cirrhosis of the
liver and an extensive portal systemic collateral circulation, who have previously
shown neurological complications. This toxicity could not be correlated with the
changes in blood ammonium levels. Intravenous methionine is apparently non-
TABLEV.




















































































































































§ 3 Q £ I
>3
&
(Bloodlevelsinjxg./ml.). *Patientswhohadpr vi uslyexperiencedneurologicalcomplicat on .
o
u>
104 PHEAR RUEBNER, SHERLOCK AND SUMMERSKILL.
toxic despite high blood methionine levels. Oral chlortetracycline given with
methionine prevented or retarded toxic effects, although blood methionine levels
were higher than with oral methionine alone. It therefore seemed likely that the
toxicity was due to some substance other than methionine. The protection afforded
by chlortetracycline suggested that this toxic factor might be derived from methionine
by the action of intestinal bacteria which were affected by the " wide spectrum "
antibiotic, and bacteriological observations were therefore made.
Bacteriological investigations.
No difference in the faecal viable count was found between nine patients without
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Effect of chlortetracycline on the faecal viable count of Streptococci.
time had neurological symptoms. CI. welchii Type A, however, was isolated in
six of twenty patients with liver disease and in only one of the nine other patients.
It was not more common in those with neurological complications.
Oral methionine did not have a significant effect on the fecal flora of seven
patients with liver disease, three of whom had neurological complications.
Effect of chlortetracycline (Figures 1-4).
Chlortetracycline was given for three to eight days to sixteen patients, thirteen
of whom had cirrhosis of the liver, all but one with neurological complications.
Two patients had three courses of the antibiotic. Seventy two specimens of feces
were examined during the three days preceding and the thirteen days following
chlortetracycline. The total viable count showed no sustained fall during therapy.
The fecal flora changed however, the picture being the same in all patients.
Lactose fermenting gram negative rods (Bact. coli) were eliminated at some
stage in ten of the sixteen patients, whereas before treatment they were absent in
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only one. The viable count during therapy fluctuated widely and some patients
showed no diminution. No increase in resistance to chlortetracycline during
therapy was detected (Fig. 4).
The total count of streptococci during treatment showed no change, but some¬
times there was a complete change of strain. In seven patients after treatment
a hemolytic Stv. fcecalis and in three patients a micro-asrophilic streptococcus,
both resistant to chlortetracycline, replaced a sensitive Str. fcecalis. A hemolytic
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Fig. 2. Effect of chlortetracycline on the faecal viable count of Bacteroides.
Proteus was not isolated from any patient before therapy. During and after
chlortetracycline, proteus appeared in thirteen of sixteen patients. Of those
organisms investigated, five were Pr. mirabilis, three Pr. vulgaris and two Pr. morganii.
Proteus was usually eliminated from the feces in two to three weeks, but in some
cases (especially after a second course of chlortetracycline), proteus persisted for
two to three months (Fig. 2).
Gram negative anaerobic bacilli (Bacteroides) were investigated in 8 patients,
and were present before treatment but disappeared before the fourth day. They
reappeared four days after the cessation of the antibiotic (Fig. 2).
In one patient a lactobacillus was present in large numbers before treatment.
In five patients chlortetracycline was followed by the appearance of resistant
lactobacilli.
Clostridium welchii Type A was isolated initially in three patients and in every
instance was eliminated by chlortetracycline.
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Fig. 4. Effect of chlortetracycline on the fecal viable count of Bad. coli.
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Staph, pyogenes resistant to chlortetracycline appeared in large numbers in
three patients during treatment.
Candida was found in large numbers in only one patient during therapy.
Detailed bacteriological results are shown in the Appendix.
Conclusion. The fecal flora of patients with liver disease with and without
neurological complications does not differ from that of subjects without liver disease.
Chlortetracycline effects an inconstant fall in Bact. coli, the strain of streptococci
often changed and proteus usually appeared while bacteroides fell and lactobacilli
frequently increased.
The action in vitro of Bact. coli, proteus and bacteroides on methionine with
and without chlortetracycline was therefore investigated.
Action ofBact. coli, Pr. vulgaris and Bacteroides on methionine.
Bact. coli, Pr. vulgaris and Bacteroides did not grow in cultures in which
methionine was the only source of nitrogen. Resting suspensions were therefore
set up in a solution of methionine. After incubation NH4 production in these
cultures was slight. In four experiments at pH 8 Bact. coli, Pr. vulgaris and
Bacteroides produced respectively 2-0 (± 1-0), 10-0 (+ 5-4) and 0-8 (± 0-7) u.g.
NH4N per ml.. Further experiments at pH 6 and with and without added glucose
gave similar results.
Since 14 yg. NH4N are equivalent to 149 yg. methionine and since 1,000 yg./ml.
of methionine were present initially, it is not surprising that no decrease in the
methionine concentration was detected. There was also no detectable increase
in SO4 production.
No evidence was obtained for methionineamine production either from
methionine alone (4 occasions) or in a mixed amino-acid medium by growing
bacteria (13 occasions), and in the latter medium, no evidence for methionine
breakdown was found, by resting suspensions (4 occasions).
Discussion.
A methionine deficient diet is followed by severe liver injury in rats (21). These
observations have been enthusiastically applied to human liver disease and methionine
is freely prescribed (8, 26). It is of importance, therefore, to realise that this amino-
acid in therapeutic amounts has been found to reproduce " impending hepatic coma "
in some patients with hepatic cirrhosis. As there is no conclusive evidence that
methionine affects the course of liver damage in man (36, 55), this therapy should
now be abandoned.
Patients exhibiting neurological deterioration after methionine all had large
collateral channels between the portal systemic venous system, with chronic portal
systemic encephalopathy (47). These patients can show a perplexing variety of
neurological and mental changes, and exacerbation by methionine may provide a
convenient method of inducing a diagnostic neurological effect. Chronic portal
systemic encephalopathy may follow a surgical porta-caval anastomosis in about
10% of patients (41), and a course of oral methionine given pre-operatively may
provide a suitable screening test to determine the likelihood of this occurrence.
The toxic effects of methionine were not related to alterations in the liver
function tests. They are not due to unaltered methionine, for there was no correla¬
tion of symptoms with the blood methionine level, which rose equally in those who
deteriorated and those who did not. The breakdown products of methionine
which might be responsible are numerous, and only a few possibilities can be
considered.
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Our in vitro studies cannot be taken as evidence that bacteria do not attack
methionine for three reasons. Firstly, metabolism of resting suspensions is often
very different from that of growing bacteria. Secondly, no attempt was made to
induce enzyme formation by growing the bacteria in the presence of high
concentrations of methionine. Thirdly, no precautions were taken while washing
the bacteria, to keep them under reduced conditions and the enzyme systems which
attack methionine may well possess sulphhydryl groups which are oxygen labile.
Ammonium can be derived from methionine and ammonium toxicity has
been related to the neurological changes which precede hepatic coma (3, 38, 42).
Ammonium production in the intestine seems unlikely to cause the deterioration
which follows methionine, for changes in blood ammonium levels were inconstant
and alterations of a similar order occurred when chlortetracyline was given with
the methionine, yet without neurological deterioration.
A further possibility is that ammonium intoxication may result from disturbed
glumatic acid metabolism (54). Glumatic acid is important for cerebral respiration
possibly by combining with ammonium to form glutamine. It has been shown that
methionine sulfoxide, a substance that can readily be derived from methionine,
inhibits this synthesis in Lactobacillus arabinosis (51). Accumulation of methionine
sulfoxide might explain the cerebral features of methionine toxicity. Moreover,
methionine sulfoxide has possibly been detected in the cerebro-spinal fluid of two
patients with hepatic coma (52). Current methods of identification, however, are
unreliable and this observation needs confirmation. Methionine sulfoxide has
proved non-toxic to dogs and rats (2, 50).
Methyl mercaptan can be produced from methionine directly (9) or via
cysteine, by proteus and sometimes by Bact. coli in the presence of glucose (24).
Recently a patient with massive hepatic necrosis and fcetor hepaticus was found
to have methyl mercaptan in the urine (10) and we have identified this substance
on two of four occasions in the urine of four patients in hepatic coma. These are
observations of great interest, although the effect of mercaptans on the central
nervous system are unknown. Some mercaptans, however, have been found to
have anti-hypertensive properties (44) and this might contribute to the hypotension
of patients with cirrhosis of the liver.
Butt and Mason (6) considered that fcetor hepaticus was due to a tertiary amine.
Methionineamine has never been isolated naturally, and we have failed to find it
on ten occasions in the urine of patients with liver disease. It could theoretically
be derived from methionine, however, and some amines are known to affect oxidative
metabolism in the brain (39, 40).
Methionine may produce acidosis from the metabolism of sulphur and inorganic
sulphate, but in the doses we used, adequate renal and pulmonary function should
compensate. In our patients, the decrease in arterial pH and blood alkali reserve
was slight. Moreover, increasing acidosis has not been reported in spontaneous
hepatic coma (7, 38, 46).
At present, the toxic substance derived from methionine and the mechanism
of its action remain unknown. Further study of the mercaptans and amines
derived from methionine seem worth while.
The observed effects of chlortetracycline on the fecal flora are in general
agreement with those of other investigators, who found some elimination of Bact.
coli and a rise in proteus, streptococci and staphlococci (14, 33). Pappenfort and
Schnall (35) noted the appearance after chlortetracycline therapy of Candida, which
we found in considerable numbers in only one patient. Loh and Baker (27) found
an individual variation. The changes they report are less marked than those
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previously described, but very similar to our own. The rise in proteus, however,
was more conspicuous in our series, but the increase in Staphlococcus pyogenes
occurred less often. We confirmed the observation of Dearing and Heilman
(14) that Bacteroides were eliminated by chlortetracycline in every patient. In
agreement with Loh and Baker, the total anaerobic count was found to be less reduced
than the count of Bacteroides ; this was due to multiplication of lactobacilli and
anaerobic streptococci.
Although the changes in faecal flora show a similar pattern, exact results of
therapy in any individual cannot be predicted. They presumably depend on the
initial presence in small numbers of strains, resistant to the antibiotic, which
multiply when sensitive organisms are depressed during therapy. McVay (29) showed
that organisms at higher levels of the intestine are suppressed earlier and to a greater
extent than those present in the feces. The changes effected in the ileum and proximal
colon, where the antibiotic is present in higher concentration, may be more clear-
cut than those seen in the feces.
The protection afforded by chlortetracycline might be due to a change in
intestinal flora, or it could be a direct metabolic effect. Chlortetracycline does
not reduce the amount of ammonium produced from methionine by bacterial
suspensions and it seems unlikely that the protection is due to less amino-acid being
metabolised.
Chlortetracycline prevents massive hepatic necrosis in rats fed on a necrogenic
diet (16, 19), an effect attributed to elimination of intestinal bacteria, which may
utilise protective constituents of food (18). This long term effect is hardly relevant
to our observations and sparing of an essential food factor seems unlikely.
Chlortetracycline might affect liver function directly, but this could not be shown
by routine liver function tests. Mann and co-workers (31) found that antibiotics
failed to reduce blood ammonium levels in patients with liver disease.
Chlortetracycline may decrease amine production in the gut (32). De la Huerga
and Popper (15) showed that chlortetracycline inhibited the formation of total
tri-methylamine from choline through suppression of choline-utilising bacteria.
The possible toxic effects of amine have already been discussed.
" Hepatic coma" shows such natural fluctuations that it is difficult to assess
therapy in any individual patient. The present observations, in which patients
served as their own control, shows that chlortetracycline is at least of benefit in
methionine-induced neurological complications of liver disease. The neurological
picture in this condition is identical with that caused by other nitrogenous substances
and that seen in many instances of spontaneous " hepatic coma ", although the
metabolic relationship between these conditions remains unknown. It does seem
worth while, however, to apply our observations to the whole group of neurological
complications of liver disease, and it is our clinical impression that chlortetracycline
therapy is of benefit in spontaneous hepatic coma.
Summary.
1. Oral methionine caused neurological deterioration in seven of nine patients
with portal cirrhosis and chronic portal systemic encephalopathy. In eight of the
nine patients, large portal systemic venous collateral channels were demonstrated.
It was without effect in seven patients with hepatic cirrhosis, three of whom had
an extensive portal systemic circulation and one with extra-hepatic portal vein
obstruction. These patients had never experienced neurological complications.
2. Intravenous methionine was without effect in three of those who reacted
to the oral amino-acid and in one there was a delayed exacerbation.
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3. Neurological deterioration occurred without significant change in blood
ammonium, blood pH, or serum bilirubin level.
4. Blood methionine levels rose equally in those who deteriorated and those
who did not.
5. Oral chlortetracycline prevented or delayed the neurological deterioration
in five sensitive patients who received methionine although the blood levels of that
substance were even higher.
6. Faecal flora of patients with liver disease and neurological complications,
did not differ from normal subjects and patients with uncomplicated cirrhosis.
7. Methionine did not change the faecal flora, but chlortetracycline in all
groups resulted in a rise in proteus with elimination of Bacteroides and an inconstant
fall in Bad. coli. The streptococcal types changed and lactobacilli increased.
8. The toxicity of methionine in patients with chronic portal systemic
encephalopathy is due to some breakdown product of methionine other than
ammonium.
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APPENDIX—continued.
Patient Organism Control
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* Case 5:—On date 5/4 bacterial counts were Bact. coli 1-9 X 10®, Str. faecalis (non-haemolytic) 5 0 X 108, Proteus mirabilis
1"0 x 10* and Bacteroides 3-3 x 10°.
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THE liver plays an important part in protein and amino acid metabolism.The function of methionine in experimental hepatic necrosis (Himsworth1)
and its metabolism in patients with liver disease (Kinsell and associates2)
have been investigated particularly carefully. Many patients with liver disease
have a high fasting plasma methionine level and are unable to metabolize
methionine. In this paper, a new method for the estimation of L-methionine
in plasma is described employing a methionine-requiring mutant of Bacterium
coli Strain K-12.
Certain mutant strains of Bad. coli Iv-12 (mutants 58/161 and J5"3) em¬
ployed in work on genetic recombination, unlike typical Bad. coli strains, can¬
not grow in a basic synthetic medium containing only glucose and ammonium
salts as source of carbon and nitrogen, respectively. Mutant 58/161 requires
L-methionine and mutant J5"3 requires both L-methionine and l-proline for
growth, and these amino acids must be added to the medium. Since as little
as 5 fxg per milliliter methionine promotes good growth of the mutants in syn¬
thetic fluid medium, whereas 0.5 /xg per milliliter still allows the develop¬
ment of a visible turbidity, these mutants appeared to be suitable for the
estimation of methionine levels in the blood. With limiting concentrations of
methionine, the amount of growth (judged nephelometrically) is proportional
to the methionine concentration.
As the methionine-requiring mutant will grow in the absence of methionine
if plasma proteins are present, a protein-free extract of the plasma must be
used for assay. Dilutions of this extract are made in fluid synthetic medium,
a small inoculum of washed bacteria is added to each, and the tubes are in¬
cubated at 37° C. At the same time, a set of standard tubes containing known
concentrations of methionine are similarly set up and incubated. After incuba¬
tion, the turbidity of each culture is compared with the standard series in a
photoelectric nephelometer.
method
1. Strains of Bacterium coli Employed.—The L-methionine-requiring strain, of Bact.
coli K-12, mutant 58/161, was principally used in this work. It was found, however, that
its requirement for methionine could be fully satisfied by either homocysteine or cystathionine,
From the Department of Pathology, Postgraduate Medical School, London, Eng.




BIOLOGIC ASSAY OF L-METIIIONINE 141
which constitute prior stages in methionine synthesis so that the biochemical block in this
strain arises before the cystathionine stage. The following amino acids and growth factors
were investigated to see whether they could support growth of this strain in the absence
of methionine: cysteine, threonine, alanine, proline, aspartic acid, glycine, tryptophane,
norleucine, glutamic acid, isoleucine, vitamin B12, choline, calcium pantothenate, para-amino-
benzoic acid, and adenine.
None of these substances was found to be capable of replacing methionine in support¬
ing growth. Recovery and dilution experiments strongly suggested that the methionine pre¬
cursors cystathionine and homocysteine were not present in biologic fluids in significant
amounts. This was confirmed by repeating some of the assays with another mutant strain
of Bact. coli K-12 (J5-3) which requires both methionine and proline. Work on genetic
recombination (Clowes and Rowleys) bad suggested that in this strain the mutation to
methionine-dependence had occurred at a different genetic locus from that of mutant 58/161.
This suggestion was supported by the finding that homocysteine and cystathionine could
not substitute for methionine in promoting growth of this mutant, nor could cysteine, vita¬
min B12, aspartic acid, or adenine. Results of assays with the two strains were very similar,
thus confirming that homocysteine and cystathionine are not normally present in the plasma
in amounts which could interfere with the assay of methionine by mutant 58/161 of Bact.
coli K-12.
2. Preparation of Inoculum.—An overnight broth culture of the assay strain was
washed three times in 0.85 per cent sodium chloride and resuspended to the original volume
in saline. One drop of this suspension (0.02 ml.) was used to inoculate the 10 ml. of medium
in each assay tube.
3. Medium.—The medium employed had the following constitution:
The pH was adjusted to 7.2 and the medium sterilized by autoclaving. Before use,
1.25 ml. of sterile 20 per cent glucose solution was added to each 100 ml., giving a final
glucose concentration of 0.25 per cent in the medium.
For assays employing strain Js-3, 20 mg. of L-proline was added to each 1,000 ml. of the
medium.
4. Preparation of a Standard Curve.—Tubes were prepared containing 10, 5, 4, 3, 2, 1
and 0.5 Mg per milliliter of L-methionine in 10 ml. medium. After inoculation with the test
organism, the tubes were incubated at 37° C. for forty-eight hours and the turbidity of
each tube measured with a photoelectric nephelometer.* The turbidity in arbitrary units
was then plotted against the concentration of L-methionine in Mg per milliliter. Between
0.5 Mg per milliliter and 5 Mg per milliliter there is virtually a linear relationship (see
5. Deproteinization of PlasmaA—Eleven and two-tenths milliliters of distilled water
was added to 8 ml. of plasma in a bottle. This was then stoppered, shaken, and 2.8 ml.
of 0.6 N H., SO, added slowly with mixing, followed by 2 ml. of 10 per cent sodium tungstatc.
The plasma was therefore diluted 1 in 3 in the preparation of a protein-free supernatant.
The bottle was then shaken for two to three minutes and centrifuged. The protein-
free supernatant was pipetted off and used for the methionine assay after adjustment of
the pH to 7.2 and sterilization by boiling for two minutes.
6. Preparation of Assay Tubes.—As the turbidity is proportional to the methionine
concentration only over a limited range, several different dilutions of the supernatant were
*An "EEL." photoelectric r.ephelometer (made by Evans Electroselenium Ltd., Harlow,
Essex, England) was used which measures, on an arbitrary scale, the amount of light reflected
by the bacteria in the suspension. In order to obtain comparable readings, the instrument
was adjusted each day so that a turbidity standard (known to be equivalent to 3.6 mg. of
protein nitrogen of Bact. coli K-12) read 100 arbitrary units.
Na2 H PO,
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usually made in the basal medium. With low concentrations of methionine, such as are
found in the fasting state, 5 ml. of plasma supernatant was added to 1 ml. of ten times
concentrated synthetic medium and the total volume made up to .10 ml. with distilled water.
Thus, the final dilution of the supernatant in the medium was 1 in 2. With higher methionine
concentrations, 1 ml. or 0.5 ml. of plasma supernatant was added to 9 or 9.5 ml. of the
synthetic medium, giving a dilution of the supernatant in the medium of 1 in 10 or 1 in 20.
7. Calculation of Plasma Methionine Concentration.—From the standard curve, the
methionine concentration in micrograms per milliliters in one of the dilutions of the super¬
natant set up was determined. This figure was then multiplied by the dilution factor of
the supernatant in the medium of the particular tube used, and also by three, which is the
dilution of the original plasma in the protein-free supernatant.
Thus: Methionine concen- Methionine concentration in Dilution of supernatant
tration in /ig per milliliter = the test tube read off the x in the medium x 3
of the original plasma standard curve
TURBIDITY IN ARBITRARY UNITS.
lOOunit&E 3-6mg. of protein nitrogen I
per IO Oral I
CONCENTRATION OF L-METHIONINE in M9-/1"1
Fig. l.—Standard curve of growth in arbitrary turbidimetric units as related to concentration
of L-methionine in medium.
RESULTS
1. Recovery Experiment.—The L-methionine in normal plasma and in the
same sample of plasma to which 100 p.g per milliliter of L-methionine had pre¬
viously been added was estimated.
NEPIIELOMETER READINGS IN
ARBITRARY UNITS
DILUTIONS OF SUPERNATANT IN
MEDIUM
ESTIMATED CONCENTRATION OF
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2. L-methionine Levels in Patients With Cirrhosis of the Liver.—Ten grams
of DL-methionine was given daily for two to six days to 9 patients with cirrhosis
of the liver. The L-methionine morning plasma levels varied from 9 to
69 ng per milliliter before the administration of methionine. They rose to 20
Ug per milliliter, or above, in every patient receiving this amino acid. In one
case, after six days a level of 375 i±g per milliliter was reached.
In a series of 10 parallel estimations of a single specimen, the average read¬
ing was 43.1 arbitrary units and the standard deviation ± 2.
DISCUSSION
Although quantitative chromatographic methods for the estimation of
amino acids in biologic fluids have recently been developed (for example, column
chromatography by Moore and Stein,5 and paper chromatography by Smith and
Tompsett6), microbiologic methods probably remain more specific and sensitive
than chemical estimations (Wheeler and Gyorgy7). The usual microbiologic
methods employ Streptococcus faecalis (Stokes and co-workers8) or Leuconostoc
mesenteroides P00 for L-methionine and Lactobacillus fermentans 36 for DL-methi¬
onine (Kinsell and associates0). All these organisms require complex synthetic
media for assay.
The Bact. coli mutants used in this method require L-methionine for
growth. Except for cystathionine and homocysteine, which can replace this
amino acid as an essential growth factor for strain 58/161, none of the amino
acids, B vitamins, and growth factors tested could replace methionine in pro¬
moting growth. Both strains gave very similar results, and it is concluded that
cystathionine and homocysteine are not present in the plasma in amounts suf¬
ficient to invalidate this assay method.
The medium used in this method is much simpler than that required by
the other test organisms. There appears to be no reason why other amino
acids and B vitamins should not be assayed by a similar method using Bact.
coli mutants.
The results obtained by this method are very similar to those of Kinsell
and associates2 who administered 9 Gm. of DL-methionine daily, as compared
to 10 Gm. in the present series. Using Leuconostoc mesenteroides P(i0, they
found that elevation of the fasting level to above 20 p.g per milliliter occurred
in all patients with liver disease, but not in normal subjects. The present in¬
vestigation thus confirms that methionine utilization is impaired in patients
with cirrhosis of the liver.
SUMMARY
A microbiologic method for the assay of L-methionine in plasma, using a
methionine-requiring Bact. coli mutant, is described. The medium used is much
simpler than that required by other test organisms. The method has been
applied to the investigation of the abnormal methionine metabolism in patients
with cirrhosis of the liver.
It is suggested that other amino acids and B vitamins might be assayed
using Bact. coli mutants.
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Large amounts of ammonium salts are normally present in portal blood and
are then metabolised to urea in the liver (Bollman and Mann, 1930). In patients
with poor liver function and a portosystemic collateral circulation, and also in
dogs with a portocaval shunt (Eck fistula), ammonium may by-pass the liver
and reach high levels in the general circulation (Burchi, 1927 ; White, Phear,
Summerskill and Sherlock, 1955). There is evidence that the presence of ammo¬
nium salts in the peripheral circulation may have toxic effects. For example,
Bollman and Mann (1930) found that ammonium salts were toxic to dogs with an
Eck fistula. A correlation between a high peripheral blood ammonium level and
nervous symptoms has been noticed particularly after administration of a high
protein diet in Eck fistula dogs (Monguio and Krause, 1934) or urea in man
(Phillips, Schwartz, Gabuzda and Davidson, 1952) or after haemorrhage from intesti¬
nal varices (Riddell, 1955).
In addition to the possible toxicity of ammonium salts there is some evidence
that methionine breakdown products, other than ammonium, may also be toxic.
Thus, Phear, Ruebner, Sherlock and Summerskill (1956) have shown that after
oral methionine certain cirrhotic patients exhibit nervous disturbances clinically
indistinguishable from hepatic coma. In view of the fact that ammonium in
particular is found in very high concentrations in the portal vein it seems probable
that its source is the intestine (Cholopoff, 1927). Since bacteria are known to
produce ammonium from both the breakdown of amino acids and the splitting of
urea, it seems likely that the ammonium in the portal vein is the result of bacterial
metabolism in the intestine. Attempts have therefore been made to treat cases
of hepatic coma by the administration of antibacterial agents. Farquhar, Stokes,
Whitlock, Bluemle and Gambescia (1950) found that chlortetracycline benefited
such patients while Phear et al. (1956) found that the nervous disturbances
following oral methionine, mentioned above, were partly or completely prevented
by the administration of the same antibiotic. Dintzis and Hastings (1953) and
Chao and Tarver (1953) found that the feeding of sulphonamides to animals
inhibits the formation of ammonium from urea in the intestine. Sulphonamides
have also been shown to lower the blood ammonium level in a patient with a
porto-caval anastomosis (McDermott and Adams, 1954). Again, Martini, Phear,
Ruebner and Sherlock (1956) during an investigation of the intestinal flora of
cirrhotics found that when ileal fluid was incubated there was an increase
of coliforms and Streptococcus faecalis with production of ammonium and break -
* In receipt of a grant from the Medical Research Council
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down of methionine. However, the addition, before incubation, ofchlortetracycline
to the ileal fluid prevented almost completely the multiplication of the bacteria
and the biochemical changes.
The object of the present study was to investigate the bacterial production of
ammonium under in vitro conditions approximating to those probably existing in
the intestine. The production of amines which may also be toxic (Melnykowycz
and Johannson, 1955) was also examined. Work on bacterial nitrogen metabolism
has mainly dealt with the action of bacterial suspensions on individual nitrogenous
substances. We studied the changes produced by bacteria growing in media
containing a mixture of amino acids. The strains used were intestinal bacteria
isolated during the investigations of Phear et al. (1956) and Martini et al.
(1956). An attempt was made to identify the principal ammonium producers
and to study the effect of chlortetracycline on their growth and ammonium
production with a view to applying rational chemotherapy to this condition or to
changing the intestinal flora by dietary means.
MATERIAL AND METHODS
Strains of bacteria
The organisms used in this investigation were isolated mainly from the faeces of patients
with cirrhosis of the liver before and after ehlortetracycline therapy (Phear et al., 1956).
A few were obtained from the ileal fluid of cirrhotic patients (Martini et al., 1956) and. a few
others from normal subjects. Strains representing each of the commoner intestinal organisms
were chosen.
Sensitivity to chlortetracycline
This was measured by a tube dilution method in 0-5 per cent glucose broth (pH 7-2).
The concentrations of chlortetracycline used varied from 250 to 0-12 gg./ml. Results were
read after 18 hr. incubation for aerobes and after 2 days' incubation in a Fildes Mcintosh
jar for anaerobes. The end-point was taken as the lowest concentration of the antibiotic
which inhibited growth. The Oxford Staphylococcus was used as a standard organism
throughout. The results of sensitivity tests were in general agreement with those of other
investigators (Ungar, 1951).
Culture media
A synthetic amino acid medium of known composition was used for most of the work.
The amino acid mixture chosen was that of Stokes, Gunness, Dwyer and Caswell (1945).
' Yeastrel' was added to (>5 per cent to supply the various members of the B group of vita¬
mins. To each litre of medium were added 5 g. NaCl, 10 mg. MgS04, 7 g. Na2HP04, 3 g.
KH2P04. The pH was adjusted to 7'2. The final nitrogen concentration was 130 mg. per
cent. The amino acids remaining after incubation were identified by paper chromatography.
A casein hydrolysate medium was used for some of the work, and had the same compo¬
sition except that the 130 mg. per cent nitrogen was derived from casein by acid hydrolysis.
A peptic digest of blood was prepared similar to that of Fildes (Mackie and McCartney,
1953) except that horse blood was substituted for sheep blood. Its nitrogen content was
adjusted to 130 mg. per cent. Yeastrel and salts were added in the same concentrations as in
the amino acid medium.
The buffer concentration (0-02 m) was insufficient to maintain the pH in the presence of
added carbohydrate, and after incubation the pH fell. The final pH values of cultures inocu¬
lated with an atypical coliform (Bacterium freundii), Proteus morgani and a non-haemolytic
streptococcus in the presence of glucose were respectively 5-2, 4-9 and 4'4.
Anaerobic conditions, when necessary, were obtained by boiling the medium and then
adding 0-01 per cent thiolacetic acid. Other substances when added were present in the
following concentrations : glucose 500 mg., lactose 500 mg. and urea 100 mg. per cent.
Medium in 10 ml. quantities was placed in 20 ml. screw-capped bottles, inoculated with a
drop (0-02 ml.) of a broth culture of each strain and incubated at 37°,
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Assessment of bacterial growth
After incubation, growth was usually assessed by the turbidity of the medium. An EEL
photoelectric nephelometer (Evans Electroselenium Ltd.) was used. In order to obtain
comparable readings the instrument was adjusted each day so that an opacity standard
read 100 arbitrary units. The amount of bacterial growth of each species was assumed to be
proportional to the nephelometer reading in arbitrary units. In order to compare the growth
of different species it was decided to assess bacterial growth in gg. N/ml. One strain of each
genus was grown in 0-5 per cent glucose broth, washed three times in 0-85 per cent sodium
chloride and re-suspended. The N content of a suspension of standard turbidity (100 arbitrary
units) was then determined.
Growth in the blood digest medium was not assessed turbidimetrically as turbidity
estimations gave irregular results believed to be due to a breakdown product derived from the
medium. When this mediumwas used in an experiment, growth was assessed by viable counts
using the method of Miles and Misra (1938). It was realised that this was less reliable for
the assessment of growth than a nephelometric method.
Time of incubation
To find the most suitable time for incubating the cultures before measuring growth and
ammonium production a series of cultures of Bad. freundii was set up and their turbidity,
viable count and ammonium content were measured daily. Growth and ammonium produc¬
tion were almost maximal after 1 day. Cultures of Bact. freundii and other aerobes were there¬
fore examined after 18 hr. incubation. Anaerobes including microaerophilic streptococci and
lactobacilli grew more slowly and were examined after 48 hr.
Biochemical methods
Ammonium production was measured by the microdiffusion method of Conway (1950).
Total nitrogen was measured by Nesslerisation.
DL-methionine wasmeasured by running the specimens, together with a range ofstandards,
on buffered filter paper (McFarren, 1951) and then extracting and measuring the concentration
ofmethionine in the spots by the method of Naftalin (1948) or of Yemm and Cocking (1955).
After making the medium alkaline, amines were extracted into ether. They were then
re-extracted into a small volume of hydrochloric acid and run on unidimensional chromato-
grams using butanol-acetic acid as solvent. Chromatograms were run on Whatman No. 1
filter paper at room temperature. They were sprayed with ninhydrin. It was not possible
to identify the amines fully, but known amines were run on each chromatogram, and their
Rfvalues compared with those of the amines produced by the bacteria. No exact quantitative
measurements of amine production were made, but the amount of substance in each spot was
graded 0 to 6.
RESULTS
Growth and ammonium production by different species
The ammonium content of the medium was increased by the growth of all the
species investigated except the lactobacilli which in some experiments did not
produce any ammonium (Table I). In the absence of glucose the various species
did not differ in the quantities of ammonium produced in relation to growth
expressed in terms of
production of NH4 nitrogen
production of bacterial protein nitrogen.
The addition of glucose to the medium, while increasing the growth of all
strains except Bact. freundii, decreased NH4 production This agrees with the
findings of Stephenson and Gale (1937). In the presence of glucose the most
potent NH4 producers were the coliform, Proteus and Bacteroides strains and the
NH4N produced in relation to growth was greater from Gram-negative bacteria
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nh4n nh4n/ nh,n nh„n/
Growth. production, growth. Growth. production. growth.
109 (27) 163(11) 1-5 68 (11) 109 (16) 1-6
— —• — 122 (38) 95 (12) 0-8
— — — 146 (39) 71 (21) 0 • 5
29 (2) 71 (1) 2-4 — . ■—•
36 (0) 184(16) 5-2 127 (53) 133 (47) 1-1
— 153 (38) 82 (6) 0-5
78 (2) 150(1) 1-9 149 (26) 128 (28) 0-9
—• — — 13 (23) 17 (6) 1-3
— — — 155 (23) 83 (62) 0-5










— —■ — 182 (91) 40 (6) 0-2
— — — 144 (77) 108 (74) 0-8
— — — 27 (15) 4 (1) 0-2
— —• — 99 (65) 8 (15) 0-08
14 (2) 42 (11) 30 74 (56) 36 (18) 0-5
— 79 (39) 25 (18) 0-3
10 (3) 48 (1) 4-8 95 (19) 39 (1) 0-4
— — 21 (24) 14 (13) 0-6
Mean . 3-9 Mean 0-4
All cultures were grown in the amino acid medium of initial pH 7-2.
production in /<g.N/ml. Standard deviations in brackets.
Average growth and NH,
(mean 0-9, range 0-5-1-6) than from the Gram-positive organisms (mean 0-4, range
0-08-0-8).
Altering the pH of the glucose-containing synthetic amino acid medium to
pH 6 and pH 8 had little effect on the growth and ammonium production of Bad.
freundii, P. mirabilis, L. acidophilus and Str. faecalis.
The substitution of lactose for glucose did not lower the NH4 production of
Bad. freundii to the same extent as glucose although this organism ferments both
sugars. On the other hand, while P. morgani (a non-lactose fermenter) was
unaffected by lactose, the growth and NH4 production of Str. faecalis in this sugar
did not differ from those in glucose.
Comparison of ammonium production in an amino acid, a casein hydrolysale and a
blood digest medium
Ammonium production in relation to growth was similar in the amino acid and
casein media but much less in the blood digest medium. The initial ammonium
content of the casein medium was 400 pg. N per ml., while those of the amino
acid and blood media were 43 and 62 jig. N per ml. Thus neither growth nor
ammonium production was related to the initial ammonium content of the medium.
In the blood medium there was little difference in the ammonium production in
relation to growth by the three strains but in the casein and amino acid media
Bad. freundii was the most potent ammonium producer followed by P. mirabilis
and Str. faecalis (Table II).
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Table II.—Comparison of Growth and Ammonium Production in
Amino Acid, Casein and Blood Media
Amino acid. Casein. Blood.
r A \ t K n ( * N
Viable NH„N NH4N/ Viable NH4N NH4N/ Viable NH..N NH4N /
count produc- viable count produc- viable count produc- viable























Average 2 0 (±0-3) 125 (±16) 63 , . 2-8 (±0-2) 142 (±12;1 50 . 3-4 (±1-0) 33 (±5) 9-7
f2-0















































Average 3-4 (±0-9) 103 (±13) 38 , . 4-4 (±11) 180 (±27;) 41 . 3-5 (±01) 57 (±8) 16
Glucose was added to all cultures.
Ammonium production expressed in /«g. NH4N/ml.
Urease activity
Table III shows the difference in ammonium production with and without
added urea, among those strains found to possess urease activity. Bad. aerogenes
and 3 species of Proteus were most active, producing more than 200 /<g. per ml.
more ammonium, in the presence of urea. Staphylococcus pyogenes and one strain
of Bad. coli had less activity, producing about 20 /i,g. more ammonium, in the
presence of urea. The breakdown of urea by Bad. coli confirmed the suggestion
of Christensen (1946) that occasional strains might possess urease activity. The
microaerophilic streptococcus and Ps. pyocyanea showed little activity, producing
only about 5/tg. per ml. additional ammonium. No urease activity was observed
in Bad. allcaligenes, a second Bad. coli strain, strains of Str. faecalis, lactobacilli,
Bacteroides or Clostridium welchii.
The effect of chlortetracycline on growth and ammonium production
When carrying out chlortetracycline sensitivity tests it was found that tubes
containing a concentration of drug which would just inhibit growth over 18 hr.
showed good growth after 40 hr. This is probably accounted for by the instability
of chlortetracycline (Ungar, 1951). Table IV shows the ammonium production in
relation to growth in the presence of quantities of chlortetracycline which partially
inhibited growth over a 40-hour period. It will be seen that chlortetracycline
decreased the ammonium production in relation to growth of Bad. aerogenes and
of a haemolytic Str. faecalis while having no effect on that of Bad. coli, Bad.
freundii, P. morgani, P. vulgaris, P. mirabilis and L. plantarum. Ammonium
production in relation to growth was increased in a micro-aerophilic streptococcus.
Amine production
A comparison was made of the amine production of Bad. freundii, P. mirabilis
and a haemolytic Str. faecalis in the amino acid, blood and casein media, and in
the last with and without added glucose, Under all conditions P, mirabilis
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produced most amines, and casein was found to be the best medium for amine
production by all species. The addition of thiolacetic acid slightly increased amine
production. Glucose, while increasing the growth of all three species, decreased
amine production by Bad. freundii and Proteus, while increasing that of the
haemolytic Sir. faecalis.
Table III.—Urease Adivity of Bacteria Possessing this Enzyme in an
Amino Acid Medium Containing Glucose




































































Table IV.—Effect of Chlortetracycline at Concentrations Just Limiting Growth on




Growth. production. Growth. production. of chlor-
( A r A n NH4N , A^ A ^ NH4N tetracycline
Average. S.D. Average. S.d. growth. Average. S.D. Average. S.d. growth, (in pg./ml.).
Bcict. freundii 104 (15) 123 (9) 1 2 86 (8) 96 (9) 1 1 . 2 5
Bad. coli 122 (40) 133 (22) 1 1 67 (4) 108 (17) 1 6 . 2 5
Bad. aerogenes 109 (24) 65 (24) 0 6 82 (20) 15 (9) 0 2 . 2 5
Str. faecalis (haemolytic) 68 (2) 45 (5) 0 6 55 (8) 10 (6) 0 2 . 50
P. mirabilis 141 (21) 107 (14) 0 8 109 (8) 103 (8) 0 9 . 50
P. morgani . 117 (17) 155 (12) 1 3 94 (11) 173 (15) 1 8 . 50
P. vulgaris . 125 (14) 122 (3) 1 0 77 (1) 147 (1) 2 0 . 50
L. plantarum 24 (5) 4 (4) 0 2 14 (4) 5 (4) 0 3 . 10
Mieroaerophilic strepto- 38 (25) 23 (7) 0 6 10 (4) 25 (8) 2 5 . 10
QOCCUS
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It appeared that amines of Rf 0-04—0-06 are agmatine, histamine and cada-
verine, while that of Rf 0-45-0-47 is probably tyramine with a front retarded by
other substances present in the extract. It is not known to which amines the other
substances correspond, but that of Rf 0-69-0-72 seems to be similar to the ephe-
drine-like spot of Melnykowycz and Johansson (1955). Spots with Rf of 0-21-0-23,
0-45-0-47 and 0-69-0-72 gave a positive Pauly's reaction.
Having determined that the casein medium was most favourable to amine
production a comparison was made of amine production by these and some other
species (Table V). Glucose was added to increase growth. P. mirabilis was most
active, and lactobacillus, Ps. pyocyanea, Bad. aerogenes and Baderoides less so.
No amines were detectable in the medium after culture of CI. welchii and Bad.
allcaligenes. It was not possible to identify all the amines produced in our cultures
but results are in general agreement with those of previous workers (Gale, 1946).
Chlortetracycline in the same subinhibitory concentrations as in Table IV
prevented amine formation by Bad. freundii and Bad. aerogenes while having
little effect on that of the haemolytic Str. faecalis and none on that of P. mirabilis
(Table V).
Table V.—Comparison of Amine Produdion by Different Species in a Casein
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All cultures were initially at pH 7-2 and were incubated anaerobically in the presence of glucose.
Numbers represent an estimation of the amount of ninhydrin-positive substance in each spot-
on an arbitary scale (0-6).
discussion
The results of our in vitro studies on ammonium production cannot unre¬
servedly be applied to the more complex conditions existing in the intestine,
although comparable quantities of ammonium were produced in incubation
experiments using ileal fluid as a medium (Martini et al., 1956). It would be of
interest to know how much ammonium is produced in the gut daily. However,
the volume of the gut fluid and its bacterial content are not known and are
probably variable. The fact that in our cultures the bacterial cell nitrogen was of
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the same order as the NH4 nitrogen produced and that the nitrogen content of the
faeces is 1-3 g. per day, suggests that this is in the order of g. rather than mg.
White et al. (1955) showed that 3 g. of NH4C1 may sometimes give rise to nervous
symptoms in patients with cirrhosis of the liver. The quantity of ammonium
produced by intestinal bacteria may therefore be of clinical significance. However,
only work on isolated intestinal loops of animals can solve this problem satisfac¬
torily. Ammonium production also occurred in a medium containing no other
source of nitrogen than a peptic digest of blood. The rise in blood ammonium
observed in cirrhotic patients after intestinal haemorrhage may therefore in part
be due to ammonium produced by bacteria from blood in the intestine. When
blood urea levels rise in cirrhosis of the liver the urease activity of Proteus and
Bad. aerogenes strains may be of clinical significance.
In our experiments cultures were made in small screw-capped bottles in order
to prevent escape of ammonium, and anaerobic conditions almost certainly
prevailed during most of the incubation period. This assumption is supported by
two observations. Firstly, Bad. freundii broke down aspartic acid, cysteine,
threonine and serine, which it attacks by dehydrogenation, rather than glycine,
alanine and glutamic acid which it would have attacked by oxidation (Fry, 1955).
Secondly, the rate of ammonium production by Bad. coli is greatest under aerobic
conditions (Stumpf and Green, 1944). Since we found no difference between the
ammonium production of Bad. coli with and without thiolacetic acid, anaerobic
conditions seem to have prevailed even without this reducing substance. As
conditions in the large intestine are favourable to the growth of anaerobic bacteria
we did not consider that our results were invalidated by anaerobiosis in our
cultures. It must be admitted that in the intestine, where mixed bacterial popu¬
lations compete for available nutrients, bacteria may not show the same degree of
ammonium production as did our pure strains in relatively simple media. Although
we found that in several species ammonium production at pH 6 and pH 8 did not
differ greatly from that at pH 7, further work on ammonium production under
more varied conditions is clearly required. In particular the metabolism of
mixed cultures of intestinal bacteria and the production of ammonium during the
early phases of growth seem to merit further investigation.
The intestinal flora of patients with cirrhosis of the liver differs from that of
normal subjects in a greatly increased number of coliforms and Str. faecalis in the
small intestine. These organisms also occur at a Higher- level in cirrhotics (Martini
et al., 1956). It does not seem probable, however, that the increased blood
ammonium levels in these patients are due to this increase in small intestinal
flora. Patients suffering from other diseases but with normal liver function may
have a similar intestinal flora without showing any clinical or biochemical
abnormality (Martini et al., 1956). It seems probable, moreover, that even in
patients with cirrhosis of the liver the majority of intestinal bacteria are situated
in the large intestine, which therefore remains the main site of ammonium
production. The increased blood ammonium levels in cirrhosis are therefore
almost certainly not due to increased ammonium production in the intestine but
to a decreased ability of the liver to metabolise ammonium or to the presence of a
collateral circulation which by-passes the liver.
Reduction in ammonium production by the intestinal flora in patients with
hepatic coma might be of benefit. As glucose was found to reduce ammonium
production by intestinal bacteria the low protein-high cai'bohydrate diet
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usually prescribed for cirrhotic patients may lower ammonium production partly by
lowering the amount of nitrogenous substrate available to bacteria and partly
because of the effect of glucose in lowering ammonium production. Lactobacilli
which produce little or no ammonium are generally believed to become prominent
in the intestinal flora when a milk diet is given (Dudgeon, 15)26). Such a diet
might therefore be of benefit to patients suffering from the nervous complications
of liver disease.
Chlortetracycline was considered to be beneficial in hepatic coma by Farquhar
et at. (1950) and more recently antibiotics have been advised for the treatment of
hepatic coma on the supposition that production of harmful' toxic metabolites
might be diminished (Riddell, 1955). Investigations of the effect of chlortetra¬
cycline on the faecal flora (Phear et nl., 1956) showed that the total viable counts
were hardly diminished. Although there was a constant depression of Bacteroides
with a partial lowering of the coliform count, the number of Proteus, anaerobic
streptococci and lactobacilli increased in many cases and Str. faecalis was un¬
affected. Replacement of Bacteroides and some coliform strains by Proteus,
another strong ammonium producer, may have occurred in the Eck fistula dogs
of Mann, Bollman, Huizenga, Farrar and Grindlay (1954) who found that oxy-
tetracycline did not lower the blood ammonium levels in these animals. Our
finding that chlortetracycline at subinhibitory levels may lower ammonium
production in vitro is of interest but of limited importance as the proportion of
strains showing this phenomenon was small.
Antibiotics affecting the principal ammonium producers, Proteus, coliforms
ancl Bacteroides, should cut down the production of ammonium by intestinal
bacteria and therefore might benefit patients in. impending hepatic coma. Chlor¬
tetracycline only fulfils these conditions partially ancl other wide spectrum anti¬
biotics such as neomycin (Poth, 1954) or a combination of two drugs would probably
be more effective.
SUMMARY
A comparison has been made of the in vitro ammonium and amine production
by different species of growing intestinal bacteria.
When cultivated in a synthetic amino acid medium containing glucose of pH
7-2 all species, except lactobacilli, produced ammonium. Gram-negative bacteria
produced more ammonium than Gram-positive organisms. Glucose increased
growth in almost all instances and decreased ammonium production. Ammonium
production was greater in a casein hydrolysate and less in a blood digest medium
than in the synthetic amino acid medium. Urease activity was high in Proteus
and Bad. aerogenes and less in Staph, pyogenes, Bad. coli, Ps. pyocyaneci and
an anaerobic streptococcus.
Amine production was greater in the casein medium than in that containing
synthetic amino acids or a peptic digest of blood. Proteus was the most active
amine producer.
Chlortetracycline at subinhibitory levels in two strains reduced ammonium
production out of proportion to its effect on growth.
As ammonium salts are toxic to patients with cirrhosis of the liver a reduction
of intestinal ammonium production might be beneficial. The use of dietary
measures and of antibiotics for this purpose is discussed.
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